On November 14th, 2012 Zomig went off-patent, opening the door for generic versions of this formidable product. As an efficacious treatment for patients suffering from migraines with or without auras, zolmitriptan is also known as Zomig, marketed by AstraZeneca.
Offered in both oral and orally disintegrating tablets, in 2.5 or 5 milligram tablets, zolmitriptan has been proven in numerous studies to be extremely effective. As migraines are headaches thought to result from the dilation of the blood vessels in the brain, zolmitriptan causes the constriction of these blood vessels, thus relieving the pain of a migraine headache. Zolmitriptan is effectual in relieving migraine headaches, however, it does not prevent headaches prophylactically. Side effects of zolmitriptan include dizziness, drowsiness, dry mouth and nausea. In a class of medications called selective serotonin (5-HT) receptor agonists, zolmitriptan should be monitored when taken by patients who take selective serotonin reuptake inhibitors or monoamine oxidase inhibitors.
Encouraging research released from the ZODIAC study group showed zolmitriptan to be highly effective for patients who experience disabling migraine pain. This study, completed by Dr Jack Klapper from Colorado Neurology and Headache Center, and published in Cephalalgia, tested the efficacy of 2.5 milligrams of zolmitriptan in treating migraines. The objective of this study was to treat patients while their pain is mild, as the particular group of patients in the study typically experience migraine attacks that are initially mild, but progress to moderate or severe. This study was randomized and placebo-controlled, and involved 280 adult patients. Zolmitriptan, administered at a 2.5 milligram dose proved to offer a significantly higher pain-free rate at the two hour mark, past the initial mild migraine pain patients experienced. In addition to these positive findings, those patients treated within the first 15 minutes of their migraine pain experienced the greatest medication benefit, leading researchers to conclude that clinical benefits appear to be more pronounced when treating early onset migraines in patients.
LGM Pharma supplies the Zolmitriptan CAS# 139264-17-8 API for research and development purposes, as well as the Zolmitriptan TEVA API for compounding in the U.S.. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.